1. CoreAge Rx Spot On — sponsored first placement
Spot On's current offer cards name hydroquinone 6%, kojic acid 6% and niacinamide, with its percentage unspecified. Plans show $165 for three months or $70 for one, with $54.99 and $69.99 monthly displays. A separate $42 claim in the formula block conflicts with those plan cards. Provider review remains required before a prescription.
The public description does not verify an individual's dispensed formula, full base, package quantity or final invoice. Those questions are central to understanding the offer. A clear entry price is helpful, but it should lead to a written quote and prescription details rather than an assumption that every order has the same total.
CoreAge's first position is the sponsored placement, not evidence of clinical superiority. Read the complete Spot On review for the advertised features and the details still needing confirmation. Ask the prescriber why this combination is being considered and how progress will be reviewed.
2. Musely The Spot Cream — several formulas under one name
Musely's family includes hydroquinone-containing and hydroquinone-free formulas. Its formula FAQ lists 6% and 12% hydroquinone options, with other ingredients varying between preparations. A doctor makes the prescribing decision; a higher displayed concentration is not a recommendation to select it.
The current auto-refill presentation is $36 per month for a two-month supply. A support article clarifies a $72 medication charge for that selected option and a separate $20 doctor visit. One-time purchase and auto-refill are different choices, so the selected checkout terms need to be read directly.
Musely also promotes a conditional result guarantee and patient-reported outcome percentages. Neither is a universal promise of improvement. The Musely review covers the policy exclusions, source inconsistencies and the difference between reported experiences and comparative trial evidence.
3. Dermatica — a personalized subscription with review features
Dermatica's US pages list hydroquinone at 4% among the ingredients available for assessed treatment. They describe a 28-day trial with a $4.99 prescribing fee, then a two-month plan presented as $29.95 per bottle and $59.90 per recurring payment. The service describes two bottles arriving at approximately 56-day intervals.
That makes billing units particularly important. A per-bottle price is not the entire card charge, and 56 days is not exactly two calendar months. Ask when the trial converts to the selected plan, what is included and how a change to treatment affects the next shipment.
The service advertises progress monitoring, formula adjustments and free dermatology check-ins. These are features to clarify, not substitutes for a specific clinical review plan. The Dermatica review separates those care arrangements from subscription logistics.
4. Skin Medicinals — physician-led selection and pharmacy fulfillment
Skin Medicinals' public workflow begins with a physician's office evaluation. The clinician selects ingredients, and the patient is then contacted about payment and delivery. This can be a meaningfully different route for someone arranging an in-person assessment or working with an existing dermatologist.
Its hyperpigmentation page shows hydroquinone options and a $48-plus starting amount. That figure does not establish a complete monthly care price or include every possible practice fee. The prescription, quantity, office arrangements and shipping option need to be known before comparing the total with another service.
The current shipping policy names several pharmacies and lists different standard-delivery charges. Auto-refill is described as an opt-in feature with a notice before processing. Our Skin Medicinals review explains why a platform's public product price and the full care pathway belong on separate lines.
5. Obagi Nu-Derm Clear — a named prescription through a physician
Obagi currently identifies Clear as 4% hydroquinone and directs readers to a healthcare provider to purchase it. We did not establish a current direct prescription price. The $125 on the separate Clear Fx page belongs to an arbutin cosmetic and cannot be borrowed as the Clear Rx quote.
The linked historical DailyMed record explicitly states that the drug and labeling are not FDA-approved. It also differs from the current manufacturer page in parts of the inactive list. The Obagi Clear review preserves those limits instead of merging the records into an assumed current formula.
Ask which exact product, quantity, evaluation and follow-up the proposed charge covers. This brand route adds another option to discuss with a clinician; it does not establish equivalent care or outcomes across these different pathways.
6. Obagi Nu-Derm Blender — a second product, not a second brand
Blender is another 4% hydroquinone prescription in the Obagi family. The current page uses a physician purchase route; a present Rx price and local stock were not established. The $125 on Blend Fx belongs to a separate hydroquinone-free cosmetic.
The Blender review dates the linked 2010 prescribing PDF and the separate 2018 DailyMed record. Historical package sizes and direction wording are not merged into a current dispensing instruction. Ask for the information applicable to the actual prescription and bottle.
This is a sixth product entry across five brands. Sharing an active percentage with Clear does not establish interchangeable instructions, and a second listing does not count as evidence that the manufacturer outperforms another care pathway.
Four questions are more useful than one score
First, is the concern adequately assessed? Second, what exactly is being prescribed? Third, what amount will be charged for what quantity and interval? Fourth, who reviews progress and decides whether treatment should continue or change? These questions can be asked of every provider without pretending that their products are identical.
Use the provider board to read one comparison topic across all six product entries. A blank or unresolved fact should stay a question for the provider. It should not be filled with a guess from an older review, a different strength or a competitor's policy.
We deliberately avoid ranking creams by percentage, multiplying a short-term supply into a recommended year of use or describing the sponsor as universally safest. Those shortcuts could make a table look decisive while removing precisely the clinical and billing details that a reader needs.
A product shortlist comes after the clinical question
FDA distinguishes lawful prescription care from unapproved over-the-counter hydroquinone skin-lightening sales. An online listing alone does not settle a product's status. Likewise, a compounded prescription is not granted FDA approval because it contains a familiar active ingredient.
A clinician should first establish what is being treated and whether hydroquinone belongs in the plan. The melasma-versus-dark-spots guide and prescription guide provide that context. Then compare the actual proposed preparation and care terms, with CoreAge's commercial position kept visible throughout.
A separate non-hydroquinone option
Our Cyspera Intensive review covers a currently listed 7% cysteamine rinse-off cream. It is an alternative ingredient record, not a seventh hydroquinone entry or proof of equivalent results. Read the current formula, source-access limitation and small-trial evidence before comparing purchase routes.